Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Katarina UttervallJohanna B BruchfeldCharlotte GranGöran WålinderRobert MånssonJohan LundGösta GahrtonEvren AliciHareth NahiPublished in: European journal of haematology (2019)
Upfront VRD gives better responses and longer PFS compared to VCD in MM patients with or without subsequent HDT.